Is Valeant Pharmaceuticals Intl Inc. Another Berkshire Hathaway?

Based on Bill Ackman’s logic, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is perpetually undervalued because the companies it buys consistently push its value up immediately after the news pops. That makes it a buy with a lot of risk.

The Motley Fool

While the title might seem totally bombastic, Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) could actually be an early-stage Berkshire Hathaway.

The reason Ackman, who has invested 20% of his capital into Valeant, believes this is because of how many acquisitions Valeant makes every year. In his eyes Valeant isn’t just a pharmaceutical company. Instead, it is a “platform company” that buys other companies to increase its own value. And if you think about the business that Berkshire is in, the comparison suddenly starts to make a little sense.

According to Ackman, Valeant is really exceptional at acquiring businesses and integrating them into the overall business. Over the past seven years, Valeant has acquired over 100 businesses, and it’s clear that the company has no intentions of slowing down anytime soon.

But here’s where Ackman really makes an interesting claim. These sort of platform companies are, according to Ackman, perpetually undervalued. Specifically, Wall Street values the business based on the assets that it currently holds, not based on the assets that it will add. This means that every time Valeant acquires a large business that will move the needle, suddenly Valeant is grossly undervalued and the price will rise.

Ackman offered two examples. When the company agreed to buy Bausch & Lomb, the stock jumped from $74 to $95. And when the company agreed to buy Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), the stock jumped from $217 to $250.

That’s great, but should you buy?

My stance on Valeant Pharmaceuticals remains the same. It is a risky company that excels at buying out other companies to grow the business. It has a considerable amount of debt and it is not going to slow down its acquisitions, especially with Ackman predicting that the company will do acquisitions worth anywhere from US$7-20 billion every year.

That being said, if Ackman is correct in his assessment, Valeant is just getting started. It has a considerable amount of room to grow, especially with how many acquisitions are taking place in the pharmaceuticals business. Therefore, I wouldn’t be surprised if this stock were to rise to $300 and higher.

However, understand that it is risky and that you should not put a significant amount of money into it. While Ackman may have 20% of his money tied up in the company, he definitely bought it when it was much cheaper, so if the shares were to drop some, he’d still probably be profitable.

And if Ackman is right and Valeant does turn into another Berkshire, then investors are going to make a lot of money.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Berkshire Hathaway and Valeant Pharmaceuticals.

More on Investing

man in bowtie poses with abacus
Dividend Stocks

How Much Would You Need in SmartCentres to Collect $250 a Month?

SmartCentres can pay an actual monthly distribution. Reaching $250 from it alone would require nearly $45,000 at recent prices.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Stock Market

One ETF or Several? How to Keep Your Investments as Simple as Possible

Here's how choosing the right mix of ETFs could help you simplify your investments while building long-term wealth.

Read more »

ETFs can contain investments such as stocks
Dividend Stocks

1 Top Dividend ETF to Buy to Generate Passive Income

Vanguard's VDY pays monthly with a 0.22% MER and a 3% yield. See what $20,000 could earn, the bank and…

Read more »

groceries get more expensive as inflation rises
Dividend Stocks

2 TSX Giants to Buy for Decades of Growth and Dividends

Royal Bank of Canada (TSX:RY) and another dividend giant worth buying up for decades.

Read more »

ETF stands for Exchange Traded Fund
Dividend Stocks

2 of the Best ETFs to Buy Now

Looking for the best ETFs to buy now? Explore how XEQT offers global stock exposure while ZAG adds Canadian bonds…

Read more »

Colored pins on calendar showing a month
Dividend Stocks

How to Turn $7,500 Into a Money-Making TFSA Portfolio

One global equity ETF and two high-yield TSX dividend stocks can turn a $7,500 TFSA into a money-making portfolio built…

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Dividend Stocks

A TFSA-Worthy Dividend Stock Paying 5.1% Monthly

Choice Properties could be a great monthly dividend stock for TFSA investors seeking attractive passive income and long-term growth potential.

Read more »

Child measures his height on wall. He is growing taller.
Stocks for Beginners

National Bank Stock: How Much Growth Am I Willing to Pay for?

National Bank’s growth is worth paying for up to a point. I’d work backwards from the share price before adding…

Read more »